Mabion draws 63 mllion pln EU funds to fund vaccines work

A Polish company working, among others on a “more affordable” vaccine against COVID-19 and a cure for rheumatoid arthritis and cancer, it can not only continue its groundbreaking research, but also set up a laboratory tailored to its needs. Most of these endeavors are supported by money from Brussels.

In recent months, the company has operated in two ways, working with Novavaks on weapons against the pandemic and taking the staple in the treatment of cancer and autoimmune diseases. It would not be possible without the Research and Development Center. Mabion built them with European Funds intended for the development of such infrastructure in enterprises. The entire investment cost PLN 172 million, of which EU funds account for more than a third of the total (more than PLN 63 million to be precise). All research procedures of the company are carried out in this center.

Only for research on monoclonal antibodies, Mabion received 4 grants for a total amount of approximately PLN 109 million. A good example of their use is the flagship drug Mabion CD20, which has recently obtained approval for clinical trials of 280 patients from no less than 35 centers located in Poland, Belgium, Georgia and Ukraine. They are necessary to submit an application for registration and authorization of the drug on the market. It is to be used not only in oncology, but also in the therapy of autoimmune diseases, such as multiple sclerosis

“We believe that the scope of clinical and analytical trials developed in the course of arrangements with regulators is sufficient to submit a registration application to the European Medicines Agency, which should take place in the second half of 2022, which is in line with our previous declarations” – says Krzysztof Kaczmarczyk, President of the Management Board of Mabion ARE.


Our privacy policy